· Published by Health Canada · Official notice
This is duplicated text of a letter from Hoffmann-La Roche Limited. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
May 2, 2013
Subject: Cases of Severe Bacterial Infection of Skin and Soft Tissue (Necrotizing Fasciitis) Reported With AVASTIN
Hoffmann-La Roche Limited (Roche), in consultation with Health Canada, has informed healthcare professionals of important new safety information regarding the use of AVASTIN® (bevacizumab).
AVASTIN is used either alone to treat a particular type of brain cancer (glioblastoma), or in combination with chemotherapy to treat cancers that have spread to other parts of the body such as colon, rectal and lung cancer.
If necrotizing fasciitis occurs, AVASTIN administration should be discontinued. Your healthcare professional will decide whether AVASTIN can be re-administered.
Patients suffering from diabetes and cancer have a greater risk of developing necrotizing fasciitis, because their body’s natural defences are lowered.
Roche will be working with Health Canada to update the AVASTIN Product Monograph accordingly.
Managing marketed health product-related side effects depends on healthcare professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing side effects are generally presumed to underestimate the risks associated with health product treatments. Any case of necrotizing fasciitis or other serious or unexpected side effects in patients receiving AVASTIN should be reported to Roche or Health Canada.
Hoffmann-La Roche Limited
Drug Safety Department
2455 Meadowpine Boulevard
Mississauga, Ontario, L5N 6L7
or call toll free at: 1-888-762-4388
or Fax at: 905-542-5864
or email to: mississauga.drug_safety@roche.com
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions or require additional information regarding the use of AVASTIN, please contact the Drug Information Department at Hoffmann-La Roche Limited at 1-888-762-4388 from 8:30 a.m. to 4:30 p.m. Monday to Friday Eastern Standard Time.
original signed by
Lorenzo Biondi, R.Ph.,C.Dir
Vice President, Medical and Regulatory Affairs
Hoffmann-La Roche Limited